Background/Aims: Lung cancer continues to be the leading cause of cancer related deaths worldwide due to its high incidence, malignant behavior and lack of major advancements in treatment strategy. The occurrence and development of lung cancer is closely related to inflammation. Thus, we conducted the present study to investigate the effects of IL-35 (Interleukin 35), a newly identified anti-inflammatory factor, on non-small cell lung cancer (NSCLC), which accounts for about 85% of all lung cancers. Methods: We first evaluated the IL-35 expression in 384 pairs of NSCLC samples and their adjacent normal mucosa by realtime PCR, ELISA (Enzyme-linked immunoassay) and tissue microarrays. Then the role of IL-35 on patient survival rates, cancer progression and their sensitivity to chemotherapy drugs were assessed. Results: IL-35 was barely expressed in the NSCLC tissues but highly expressed in the adjacent normal tissues. The down-regulation of IL-35 was significantly correlated with the results of American Joint Committee on Cancer stage, differentiation and it was also shown to be an independent prognostic indicator of disease-free survival and overall survival for patients with NSCLC. Overexpression of IL-35 in NSCLC cells suppressed cell migration, invasion, proliferation, colony formation through suppressing β-catenin. IL-35 inhibited NSCLC formation in the mice model and sensitize the cancer cells to chemotherapy drugs. Conclusion: Our results showed that IL-35 plays an inhibitory role in NSCLC development and function as a novel prognostic indicator and a potential therapeutic target.
Introduction
Lung cancer is currently the most common cause of tumor related mortality in the world [1] [2] [3] . There are two main subtypes of lung cancer, small-cell lung carcinoma and non-smallcell lung carcinoma (NSCLC), accounting for 15% and 85% of all lung cancer, respectively [1] [2] [3] [4] . Clinically, NSCLC is frequently diagnosed at advanced stages of disease [4] . Over half of patients diagnosed with lung cancer die within one year of diagnosis and the 5-year survivals are around 17.8% [1] [2] [3] . Moreover, NSCLC patients are relatively insensitive to chemoand radio-therapy [4] . Despite advances in early detection, radical surgical resection, and multimodal therapeutic modalities over the recent decades, the long-term survival remains poor due to the high rate of recurrence and metastasis [1] .
Therefore, there is an urgent need to identify novel biomarkers that will help select the patients with high chance of lung cancer recurrence and uncover the underlying mechanisms which would provide better targets for NSCLC treatment. Dysregulated inflammatory response is related to an increased risk of chronic disease and cancers, including lung cancer [5] . And pro-inflammatory cytokines play an important role in many tumor related processes, including growth, metastasis, apoptosis and angiogenesis [6] . Interleukin-35 (IL-35) is a newly discovered member of the interleukin family with anti-inflammatory and immune inhibitory effects [7, 8] . Recently, it has been demonstrated that IL-35 plays an important role in tumor progression, including lung cancer [9] , pancreatic cancer [10] , nasopharyngeal carcinoma [11] , gastric cancer [12] , hepatocellular carcinoma [13] [14] [15] , breast cancer [16, 17] , renal cell carcinoma [18] and colorectal cancer [19, 20] . However, the underlying mechanisms of IL-35 in NSCLC remain unknown.
Thus, we conducted the present study to investigate the effects of IL-35 on NSCLC. To address the function of IL-35 in NSCLC, we first evaluated IL-35 expression in the human NSCLC tissues; then the IL-35 function was assessed in vitro and in vivo in a xenografted lung tumor model. The results indicate that IL-35 might play an important role in NSCLC progression and function as a novel prognostic indicator and a potential therapeutic target.
Materials and Methods

Patients
A total of 384 patients were histologically verified NSCLC at the First Affiliated Hospital of Henan University between 2004 and 2014 were enrolled in this study. The median age of the patients was 55.6 years (range 29-76 years). None of them received any preoperative anticancer treatment prior to sample collection. This study was approved by the local ethics committee of the First Affiliated Hospital of Henan University and written informed consent was obtained from each patient. All 384 specimens were reevaluated with respect to their histological types, differentiation status, smoking status, and tumor TNM stages. Tumor stages were determined by TNM classification according to the 2002 International Union against Cancer guidelines. The histological diagnosis and grade of differentiation of the tumors were defined by evaluation of the hematoxylin and eosinstained tissue sections, according to the World Health Organization guidelines of classification (2004) . Tissues were collected within 1 h after surgery. Every patient specimen included two matched pairs, namely, NSCLC tissues and adjacent normal lung tissues (≥5 cm away from the tumor). For each specimen, half were immediately flash-frozen in liquid nitrogen and then frozen at −80 °C until RNA and protein extraction was performed, the remainder was fixed with formalin for immunohistochemistry.
RNA extraction and real-time polymerase chain reaction (RT-PCR)
Total RNA was extracted from samples with Trizol (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions. Then the quantity and purity of RNA was determined by absorbance on a FilterMax F5 Multi-Mode Microplate Reader (Sunnyvale, California, USA) at 260 nm and 280 nm. Samples with ratios from 1.8 to 2.0 were accepted for next reverse transcription reaction. cDNA was prepared by using the iScript™ cDNA Synthesis kit (Bio-Rad, USA). β-actin was used as internal control. RT-PCR amplification reaction was prepared with the SYBR Green PCR kit (Bio-rad, USA) and performed using the 7500 fast RealTime PCR system (Applied Biosystems, USA). PCR products were verified by melting curve analysis. Relative mRNA levels of target genes were calculated by the 2 -ΔΔct method.
Enzyme-linked immunoassay (ELISA)
The protein level of IL-35 was detected in tumor homogenate using human IL-35 ELISA kit (AdipoGen AG, Liestal, Switzerland) according to the manufacturer's instructions. All samples were assayed in triplicate.
Western blotting
Total protein from tumor tissues and cultured cells were lysed in RIPA buffer with protease inhibitor (Beyotime, Shanghai, China). The protein was quantified using a BCA assay kit (Beyotime, Shanghai, China). A total of 20 μg of total protein were separated by 10 % SDS-PAGE, transferred onto polyvinylidene fluoride membranes, and then reacted with primary antibodies against EBI3 (Thermo Scientific, USA), β-catenin and β-actin (Abcam, Cambridge, UK). After being extensively washed with PBS containing 0.1 % Triton X-100, the membranes were incubated with alkaline phosphatase-conjugated goat anti-rabbit antibody for 30 min at room temperature. The bands were visualized using 1-step TM NBT/BCIP reagents (Thermo Fisher Scientific, Rockford, IL) and detected by an Alpha Imager (Alpha Innotech, San Leandro, CA).
TMA (Tissue Microarrays) construction and immunohistochemistry
Formalin-fixed, paraffin-embedded samples, including primary tumors and paired normal mucosa, were analyzed. Representative areas of tissue were established by microscopic review of H&E stained slides and 2.0mm diameter cores were punched from the paraffin blocks. Two cores from each of primary cancer and normal tissues at a distance of at least 2 cm from the tumor were arrayed. TMAs were created using a Tissue Microarrayer (Beecher Instruments, Sun Prairie, WI, USA). All specimens were examined by at least two pathologists to prevent bias. Tumor and normal mucosa morphology on the arrays were validated as having high accordance with that of the whole archived section.
For IL-35 immunostaining, a microwave-based antigen retrieval process was employed with EDTA buffer, pH8.0, for 30 min. After the sections had been cooled, endogenous peroxidase was inhibited with 3 % hydrogen peroxide for 10 min at room temperature. Non-specific binding was blocked with fetal calf serum for 15 min before incubation of the sections with mouse anti-human IL-35 antibody (Thermo Scientific, USA) at 4 °C overnight. As a negative control, sections were incubated with normal mouse IgG. After being incubated with the primary antibodies, the sections were then incubated with horseradish peroxidase (HRP)-labeled anti-mouse IgG at 37°C for 30 min, followed by visualization with 3, 3-diaminobenzidine (DAB) and counterstaining with Mayer's hematoxylin. Desired color reaction was observed when monitored with the microscope.
Based on the intensity and extent of staining the immunohistochemically stained slides were reevaluated by two independent observers who were blinded to patient information. . The intensity and extent score were then summed up to give a total score ranging from 0 to 6, with a total score of 0 to 2, 3 to 4, and 5 to 6 defined as no expression, weak expression, and strong expression of IL-35.
Recombinant human IL-35 protein expression
Interleukin-35 gene (homo species, EBI3 and IL-12p35 individually) was amplified from cDNA of peripheral blood mononuclear cell. The PCR fragments were double digested with restriction endonucleases and ligated into the prokaryotic expression vector. The protein was expressed in a stable prokaryotic expression system. The plasmids of positive clones were then sequenced by Sanger method with 100% identify with the published sequence. The induced and un-induced cultures were analyzed by SDS-PAGE to identify the expression of recombinant protein. The harvested cells were resuspended in NaCl-Tris-HCl buffer, sonicated in an ice bath, 12000 rpm centrifuged for 30 min, and then the supernatant were collected. The supernatant were added to His Trap HP, 1 ml column (GE) that had been equilibrated with NaClTris-HCl buffer. Different concentrations of imidazole buffer were used to elute the recombinant protein.
Collected target protein peaks were examined by SDS-PAGE electrophoresis and immunoblot analysis using 
Cell culture
The A549 and SK-MES-1 human NSCLC cell lines were obtained from the American Type Culture Collection (ATCC; Rockville, MD, USA) and cultured in DMEM (GIBCO, Shanghai, China) supplemented with 10 % FBS. Recombinant human IL-35 (rhIL-35, EBI3: IL-12p35 = 1:1) protein, with a concentration ranging from 0 to 100 ng/mL (0, 1, 10, 100 ng/mL), was added to the medium after cultured for 24 h.
Cell viability assay
Cell viability was evaluated using CCK-8 (Beyotime, Shanghai, China) according to manufacturer's instructions. Briefly, cells were seeded into 96-well plates at 5 × 10 3 cells per well and cultured for indicated time points. 10 μl of CCK-8 solution was added into the culture medium in each well. After 1 hour incubation, OD values were read using a microplate reader (Bio-Tek Company, Winooski, VT, USA) at the 450-nm wavelength. Each time point was repeated in three wells and the experiment was independently performed for three times.
Cell apoptosis assay
Cell apoptosis was evaluated by flow cytometry using an Annexin V-FITC Apoptosis Detection Kit (KeyGen Biotech Co. Roche, Nanjing, China). Briefly, cells were seeded into 24-well plates at 1 × 10 5 cells per well and cultured for 48 h. Then the cells were detached by trypsinization, washed twice in PBS (2000 rpm, 5 min; Allegra X-12R centrifuge; Beckman Coulter, USA), and resuspended in 500 μL binding buffer. A volume of 5 μL Annexin V-FITC and 5 μL propidium iodide was added and mixed gently, and the cells were stained in the dark for 10 min at room temperature. The cells were analyzed immediately by flow cytometry (BD FACSCalibur, BD Bioscience, San Diego, CA, USA) and analyzed using Flowjo software (FlowJo, Ashland, OR, USA). The experiment was repeated three times.
Cell migration assay
The migration of cells was detected by wound-healing assay. Cells were cultured in 6-well plates. When the cells grew to 80-90 % confluence, a wound in a line across the well was made by a plastic pipette tip. The area of cell-free wound was recorded 24 h after incubation with rhIL-35 protein using an inverted microscope and analyzed by the NIH Image 1.55 software. % Wound healing = 100x (1-the remaining cellfree area/the area of the initial wound). All tests were performed in triplicate.
Transwell invasion assay
Invasive ability of cells was determined within a transwell system. 6.0 ×10 4 cells were seeded onto the upper surface of the transwell membrane and cultured at 37 °C in 5% CO 2 for 24h, 48h and 72h.The number of cells that migrated to the lower surface of the membrane was counted under a microscope (200×).
Clonogenic assays
The cells were plated at either 1x10 3 cells per well in 6-well plates in standard growth media. The cells were allowed to form colonies for 10 days before being fixed and stained with 0.2% crystal violet (w:v) in 10% buffered formalin. Colony numbers were manually counted. 
Animal study
Production and in vivo Delivery of Adeno-associated Virus
Vector construction, production, and in vivo delivery of adeno-associated virus (AAV) were performed based on the AAV helper-free system (Agilent). The recombinant adenoviral vector pAAV-IL35 (EBI3-2A-IL12p35) was constructed by cloning the cDNA encoding region into pAAV-ITR. The vector pAAV-GFP encoding green fluorescence protein was used as a negative control. Recombinant AAVs were produced by HEK293 cells (ATCC) transfected with pAAV-ITR vectors together with pAAV-RC and pHelper plasmids, and then purified by discontinuous iodixanol gradient centrifugation. Purified recombinant AAVs were concentrated and desalted by centrifugation through Amicon Ultra 30K filters (Millipore). For in vivo delivery, recombinant AAVs equivalent to 1.0 x 10 12 viral genome copies were delivered though mouse tail vein.
Chemotherapy assay
Cells were treated with 5-Fluorouracil (1.5μM, Sigma), Cisplatin (1.5μM, Sigma), and Doxorubicin (30nM, Sigma) for 24 hours. Then the cells were plated at 1x103/well in 6-well plates. 10 day later, cells were fixed and stained with crystal violet. Dye was then solubilized with 1% SDS and OD590 was measured.
Statistical analysis
Data were expressed as mean (±SE) and analyzed by a SPSS software package (SPSS Standard version 13.0, SPSS Inc, USA). Differences between variables were assessed by the Chi-square test. Survival analysis of patients with colorectal cancer was calculated by Kaplan-Meier analysis. A log rank test was used to compare different survival curves. A Cox proportional hazards model was used to calculate univariate and multivariate hazard ratios for the variables. Unpaired Student's t test and one way ANOVA were used as appropriate to assess the statistical significant of difference. P values under 0.05 were considered statistically significant.
Results
Decreased IL-35 expression in human NSCLC
A total of 384 cases with NSCLC were followed ( Table 1 ). All these patients had received no pre-operation chemotherapy. They were given the same radical operation and underwent the same adjuvant chemotherapy after the surgery. We first analyzed IL-35 expression in 384 NSCLC specimens. The data showed that the mRNA and protein levels of IL-35 in NSCLC tissues were lower than its paired adjacent non-cancerous tissues (Fig.  1A, B) , and this was further confirmed by western blot analysis (Fig. 1C) .
Immunohistochemical analysis on a tissue array showed that the lack of IL-35 expression was associated with lymph nodes metastasis significantly (Table 1, Fig. 1D ). The lack of IL-35 expression also showed a positive result with the American Joint Committee on Cancer (AJCC) stage (P = 0.011) and differentiation (P = 0.001).
Patient follow-up was carried out for all patients who had undergone curative operations. Kaplan-Meier curves with a log-rank test for overall survival (OS) and disease-free survival (DFS) was conducted to assess the predictive role of IL-35 for distant metastasis. There was a significant difference between IL-35 positive and negative groups after the surgery (Fig. 1E) . Patients with IL-35 negative tumors subsequently developed more metastasis or local recurrence than those with IL-35 positive tumors (P < 0.01). When compared with patients with IL-35 positive tumors, the DFS rate was significantly lower in patients who had IL-35 negative primary tumors (Fig. 1E , log-rank test, P < 0.001). Kaplan-Meier analysis also revealed that IL-35 expression was significantly relevant to OS of NSCLC patients (Fig. 1E , log-rank test, P < 0.001). Patients with IL-35 negative tumors had a significantly lower 5-year OS than those with IL-35 positive tumors. Univariate analysis showed that patients with IL-35 negative NSCLC had a significantly lower DFS and OS than those with IL-35 positive tumors (Table 2 ). In multivariate analysis with clinicopathologic parameters, the lack of IL-35 expression was found to be an independent prognostic marker to predict tumor recurrence (Table 3) .
Taken together, these results suggested that the decrease in intratumoral IL-35 expression might be associated with NSCLC progression and associated with poor clinical outcome in human NSCLC. Fig. 2A, B) . Additionally, IL-35 promoted the apoptosis of A549 and SK-MES-1 cells in a dosedependent manner (Fig.  2C) . Moreover, IL-35 dampened the proliferation of A549 and SK-MES-1 cells (Fig. 2D) . Furthermore, their clone formation capability was also reduced by IL-35 (Fig. 2E, F) . This was further validated on newly isolated NSCLC cells (Fig. 3) .
These results indicated that an appropriate concentration of IL-35 was efficient to inhibit the migration, invasion and proliferation, and accelerate the apoptosis of NSCLC cells. Furthermore, the IL-35 could reduce the number of cancer stem cells.
IL-35 inhibits β-catenin expression in NSCLC cells
We further investigated the underlying mechanism of anti-tumor effects of IL-35 in NSCLC cells. The expressions of β-catenin in A549 and SK-MES-1 cells were analyzed after treatment with 100 ng/mL rhIL-35 for 24 h, because of the important role of β-catenin in NSCLC development [21] . The mRNA and protein levels of β-catenin were suppressed by IL-35 in these two cell lines (Fig. 4A, 4B ). To further confirm the correlation between IL-35 and β-catenin signaling pathway, we transfected the A549 and SK-MES-1 cells with plasmids overexpressing IL-35, β-catenin or them together. Compared with the control group, the effects of IL-35 on cell migration, invasion, apoptosis, proliferation and cancer stem cells were abolished in β-catenin overexpressing cells (Fig. 4C-H) . This was further validated on newly isolated NSCLC cells (Fig. 5) . Taken together, these results suggest that IL-35 may inhibit NSCLC cells via β-catenin pathway. 
Overexpression of IL-35 suppresses NSCLC development in vivo and increases the sensitivity to chemotherapeutic drugs
To investigate the role of IL-35 in tumorigenesis, a xenograft NSCLC model was used. The SK-MES-1 cells were cultured, collected and injected into the mice. After each tumor reached macroscopic size, pAAV-IL35 was administered by intravenous injection weekly for 4 weeks. The IL-35 therapy could suppress the tumor growth significantly (Fig. 6A, 6B ). Tumor cells were isolated from the mice and then subjected to chemotherapeutic drugs. Data showed that IL-35 treatment sensitize the NSCLC to these drugs, including 5-Fluorouracil, Cisplatin and Doxorubicin. These results suggest that IL-35 plays a vital role in suppressing tumorigenicity in vivo and might sensitize the tumors to chemotherapy.
Discussion
Lung cancer is one of the most common malignancies worldwide, and it remains the leading cause of cancer related death with low early stage diagnosis rate. Due to the complexity and heterogeneity of this disease, the early diagnosis of lung cancer can improve survival rate [19] . Therefore, more efforts should be made to uncover the underlying mechanisms and develop novel therapeutic targets.
IL-35 has been identified as a natural suppressor of innate inflammatory and immune responses [7] . It is highly expressed in inflammatory tissues to inhibit the excessive inflammatory response. Recent studies indicate that IL-35 plays an important role in tumor progression. However, there is little information about how IL-35 influences the pathogenesis of NSCLC development, progression, and prognosis. The function of IL-35 in tumor is largely unknown. Inflammation is the seventh hallmark of tumors [22] , inferring that IL-35 might influence inflammation related tumors. Here, we provided the evidences that IL-35 suppresses the NSCLC progression through β-catenin suppression.
In the current study, we first investigated the expression pattern of IL-35 protein in NSCLC patients. We found that IL-35 was expressed in non-tumor tissues and it was down- progression [21] . To gain further insight into the role of IL-35 in NSCLC, we examined the expression of β-catenin. We found that IL-35 down-regulated the expression of β-catenin in both mRNA and protein level. In our study, the reduced expression of β-catenin may explain the antitumor and anti-proliferation activity of IL-35. Furthermore, we also confirmed the anti-tumor effects of IL-35 in the mice model of NSCLC and demonstrated that IL-35 could sensitize the NSCLC to chemotherapeutic drugs.
In conclusion, our data showed that IL-35 expression is lower in the NSCLC. By inhibiting β-catenin expression, IL-35 impeded the NSCLC development. Thus, IL-35 could be a potential candidate for immunotherapy in NSCLC. However, the manner in which IL-35 diminished the expression of β-catenin in NSCLC is not clear.
Conclusion
Our results indicate that IL-35 is decreased in human NSCLC and IL-35 is capable of exerting anti-tumor activity by suppressing the β-catenin expression. Our findings suggest that IL-35 may have clinical potential not only as a promising prognostic predictor to identify individuals with poor prognostic potential, but also as a novel therapeutic target in the treatment of NSCLC.
